KANSAS CITY, Mo., March 31, 2025 /PRNewswire/ — Lockton, the world’s largest independent insurance brokerage, has announced today the unification of its U.S.-based Lockton Financial Services (LFS) and International ProFin teams under a single, global practice: Lockton Professional and Executive Risk.

This strategic integration brings together the expertise of more than 750 talented Associates worldwide into a single platform designed to further enrich Lockton’s ability to create and deliver best-in-class client value.

The new structure supports what Lockton has always done best—go beyond traditional insurance offerings by delivering an insurance and risk management experience that brings a truly global perspective. With greater global connectivity, Lockton Professional and Executive Risk will help clients address their professional, executive, financial, and cyber risks no matter where they operate.

“In today’s complex and interconnected environment, companies and their boards require a trusted partner that sees their risk holistically,” said Devin Beresheim, Executive Vice President and U.S. Head of Professional and Executive Risk at Lockton. “Lockton Professional and Executive Risk delivers tailored solutions to help corporate boards and C-suite executives proactively mitigate their most pressing risks on a global level, so they can focus on growing their business.”

“Through our globally connected team, we can ensure even broader knowledge sharing, deeper risk insights, and the ability to anticipate emerging threats with greater response and precision,” said Leo Flindall, U.K. Head of Professional and Executive Risk at Lockton. “The launch of this unified team is another milestone for Lockton, reflecting our commitment to continually improving our standard for client service.”

Lockton Professional and Executive Risk serves clients across a range of industries, delivering global insurance broking, risk advisory, and claims support for all major financial and professional insurance lines. Areas of expertise include directors and officers liability, cyber, general partnership liability, errors and omissions/professional indemnity, employment practices liability, fidelity/crime, fiduciary liability, insurance solutions for digital assets.

About Lockton

What makes Lockton stand apart is also what makes us better: independence. Lockton’s private ownership empowers its 12,500+ Associates doing business in over 140 countries to focus solely on clients’ risk, insurance and people needs. With expertise that reaches around the globe, Lockton delivers deep industry knowledge and product specialization with a passion for serving clients.

Logo – https://mma.prnewswire.com/media/2342384/Lockton_70_mm_Black_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lockton-launches-professional-and-executive-risk-transforming-its-global-financial-lines-business-302415279.html

Advertisement

• This major acquisition in Ticino will allow the two companies to combine their forces of production, chemical and biological expertise, know-how and technological capabilities, creating new opportunities of growth and driving business development to establish itself as an international quality leader in the CDMO (Contract Development and Manufacturing Organization) industry.
• 65 Equity Partners backs merger, partnering with these family businesses and entrepreneurs in this acquisition and merger process to drive long-term company growth and innovation.

The transaction remains subject to regulatory and tax clearances.

BIASCA, Switzerland, March 31, 2025 /PRNewswire/ — HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, today announces the planned acquisition of Cerbios-Pharma SA (“Cerbios”), a globally recognised manufacturer of chemical and biological APIs, including in the fast-growing area of antibody drug conjugates (ADCs). Both companies are based in Switzerland and sell globally.

The acquisition is supported by 65 Equity Partners, a global investment firm dedicated to supporting family-owned businesses, founders, and entrepreneurs. As part of the transaction, 65 Equity Partners becomes a c.40% shareholder alongside the Braglia family who retain majority ownership.

The combination of HAS and Cerbios creates a highly complementary and integrated leader in the Contract Development and Manufacturing Organization (CDMO) industry. Together, the two companies bring extensive production, chemical and biological expertise, technical excellence, and a broader range of services to meet the evolving needs of the global pharmaceutical industry.

With the strategic backing of 65 Equity Partners, the new Group is uniquely positioned for growth in an industry underpinned by strong structural tailwinds. These include rising demand for complex therapies and continued innovation in drug development across oncology, neurology, endocrinology, dermatology, rare diseases, gastrointestinal and other key therapeutic areas.

Importantly, HAS and Cerbios will continue to be guided by the strong corporate culture and family ownership values that have long defined both companies, with a firm commitment to Switzerland’s Ticino region remaining at its core.

The operation represents a pivotal moment for the growth of HAS and Cerbios and reflects the continuous investments that have been made to ensure excellence and technological development.

“We are excited about this operation, which marks a significant milestone in our global expansion strategy. By merging complementary skills and resources, we are confident that we can provide our clients with innovative, personalized, and high-quality solutions, further enhancing our capacity to meet market demands. Together, we are ready to achieve new milestones and strengthen our position as market leaders, striving for excellence and innovation in our industry. This transaction is of key importance for Ticino as it strengthens the reputation of the region’s chemical-pharmaceutical industry on a global level. We are pleased to welcome 65 Equity Partners as strategic partners and look forward to working closely with them to realize our vision for the enlarged Group”, explains Riccardo Braglia, CEO of 3B Future Holding SA and Board Member of HAS Healthcare Advanced Synthesis SA.

“We are delighted to partner with the Braglia family to bring together two highly complementary businesses that are trusted partners to some of the most admired pharmaceutical companies worldwide. This industry continues to benefit from strong structural growth drivers, including demographic trends, scientific breakthroughs, and growing demand for advanced therapies, making it both attractive and resilient over the long term”, comments Pascal Heberling, Partner and Co-Head of Europe, 65 Equity Partners. 

“This is a transaction that has been planned for a long time to create an internationally important chemical-pharmaceutical hub in Ticino. With the differentiated pipelines and clients of both companies, we will reach new milestones together and further improve the quality of the services offered to our clients. This joint commitment not only strengthens our market position but also reflects the commitment of both companies to the innovation project. We are also bringing together a combined workforce of over 400 people who will be at the heart of this new company. We are deeply grateful for their contribution and dedication as we look to the future with confidence, continuing to grow and innovate together”, states Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis SA.

“We are proud to join HAS Healthcare Advanced Synthesis SA and to significantly contribute to the strength and growth of the new Group. HAS represents the ideal partner to help us accelerate our growth and expand our range of offerings and the value we provide to our clients”, adds Christian Suà, CEO of Cerbios-Pharma SA. 

Advertisement

65 Equity Partners’ investment in HAS aligns with its strategy of supporting high-quality founder, entrepreneur and family-owned businesses with strong growth trajectories and distinctive technical capabilities. The firm’s long-term, partnership-driven approach and vision allows founders and families to scale while preserving their ownership and core values. This investment exemplifies that model supporting the creation of a leading international platform with opportunity for organic growth, deeper customer engagement, and selective acquisitions. 65 Equity Partners will work closely with the leadership team to help realize this vision and further strengthen the Group’s position as a premier provider of complex pharmaceutical ingredients.

HAS was advised by Rothschild & Co (financial), Bär & Karrer (legal), and EY (accounting / tax).

65 Equity Partners was advised by UBS AG (financial), Ropes & Gray and Walder Wyss (legal), EY (accounting / tax), Pharmacloud and Guidance Pharm (commercial), JensonR+ (regulatory) and Orbsen (technical).

About HAS Healthcare Advanced Synthesis SA

HAS Healthcare Advanced Synthesis, is a CDMO with four decades of international experience; the company offers a full range of customized services, from development to production. HAS Healthcare Advanced Synthesis SA develops and manufactures active pharmaceutical ingredients (APIs), highly potent active pharmaceutical ingredients (HPAPIs) and anticancer compounds.

The production site, founded in 1984, is located in Biasca, Switzerland. The facility is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. HAS operates dedicated production plants with production capacities ranging from a few hundred grams to tens of kilograms for highly potent active ingredients (HPAPIs) and anticancer compounds, and from kilograms to tens of tons for standard active ingredients (APIs); the plants are fully dedicated to cGMP production.

For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin

About Cerbios-Pharma SA

Cerbios-Pharma SA (Cerbios), has almost 50 years of experience in the industry and expertise in developing and manufacturing generic APIs as well as offering CDMO services, manufacturing APIs, HPAPI, ADCs, and biological probiotics for the international human and animal market.

Cerbios has two production sites in Switzerland (Lugano, Headquarter and Couvet). Both facilities are regularly inspected by SwissMedic, the FDA and other global regulatory agencies. Cerbios has a specialized presence in the market as CDMO service provider, with dedicated production plants. 

Advertisement

For more information visit our website https://www.cerbios.ch/ and follow us on Linkedin

About 65 Equity Partners

65 Equity Partners is a global investment firm that partners with founders, families, and entrepreneurs across Europe, North America, and Asia to build sustainable, long-term value. We invest in leading businesses across the healthcare, industrial, business services, technology, and consumer sectors.

Backed by Temasek as an independently managed investment platform with US$3.3 billion in funds under management, we provide equity and structured capital solutions to established companies with regional or global growth ambitions. With offices in London, Singapore, New York, and San Francisco, we leverage our local roots, international network and the deep expertise of our broader ecosystem.

For more information, visit our website at https://www.65equitypartners.com/ and follow us on LinkedIn.

For further information, contact:

HAS Healthcare Advanced Synthesis SA
Biasca, Switzerland
Press Office:
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: mediarelations@hashealthcare.com

65 Equity Partners 
Greenbrook
Peter Hewer, Theo Bryan, Long Tran
Email: 65EP@greenbrookadvisory.com 

Logo – https://mma.prnewswire.com/media/2652221/65_Equity_Partners_Logo.jpg
Logo – https://mma.prnewswire.com/media/2652224/HAS_Logo.jpg
Logo – https://mma.prnewswire.com/media/2652222/Cerbios_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/has-healthcare-advanced-synthesis-sa-acquires-cerbios-pharma-sa-to-create-leading-international-group-in-the-cdmo-sector-backed-by-65-equity-partners-302415465.html

Advertisement

VICTORIA, Seychelles, March 31, 2025 /PRNewswire/ — MEXC, a leading global cryptocurrency exchange, has announced a groundbreaking partnership with Mantle (MNT) to launch an exclusive month-long trading campaign with a prize pool of up to $1,000,000, offering users an opportunity to earn substantial rewards.

The event presents a range of valuable opportunities for users:

• Zero trading fees on MNT Spot and Futures markets, helping users reduce costs and optimize returns.
• Up to 500% APR through MNT staking, offering one of the most competitive yields currently available.
• Token rewards via Launchpool, where users can stake USDT, MX, or MNT to earn additional MNT tokens and exclusive benefits.

Additionally, users can join the Deposit & Trade campaign, designed with a low entry threshold—ideal for newcomers looking to explore the ecosystem. For seasoned traders, the Futures Trading Competition provides a platform to demonstrate their trading expertise, climb the leaderboard based on trading volume, and compete for a share of the $300,000 prize pool.

Event Overview

Period: March 31, 2025, 10:00 – April 30, 2025, 10:00 (UTC)

During the event period, users can participate in the following MNT-related activities on the platform by clicking on the links below.

Event 1: MNT trading (Spot and Futures) is available with zero trading fees.

Event 2: Users who deposit and trade MNT on the Spot market may qualify to share a pool of 113,340 MNT.

Event 3: MNT staking offers returns of up to 500% APR, subject to platform terms.

Event 4: A Futures Trading event allows participants to compete for a share of 300,000 USDT in bonus rewards.

Event 5: The MNT Launchpool enables users to stake selected tokens in exchange for a portion of 240,000 MNT in rewards.

Advertisement

As a pioneering Layer-2 scaling solution for Ethereum, Mantle uses Optimistic Rollup technology to lower transaction costs and improve network performance. This collaboration highlights MEXC’s leadership in backing innovative blockchain projects and its unwavering commitment to offering users diverse, cutting-edge trading opportunities, lowering costs and helping them maximize their potential returns.

Looking ahead, MEXC is committed to continuously enhancing the trading experience by introducing innovative features, expanding user opportunities, and launching new initiatives aligned with the dynamic nature of the cryptocurrency market.

For further details on the event, please see the official announcement.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 34 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.

MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

Risk Disclaimer:

The information provided in this article regarding cryptocurrencies does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, the fundamentals of projects, and potential financial risks before making any trading decisions.

Photo – https://mma.prnewswire.com/media/2653614/1920×1080.jpg
Logo – https://mma.prnewswire.com/media/2645195/MEXC_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mexc-unveils-mnt-promotion-offering-up-to-1-million-in-rewards-302415363.html